Genetics

Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024

Retrieved on: 
Thursday, May 9, 2024
Singular, Labroots, Genetics, Genomics, DSM-IV codes, Mass, Networking hardware, Travel, Health, QIAGEN, Doctor of Philosophy, Research, Gene, Scale, NGS, Knowledge, Entrepreneurship, Future, Bio-Rad Laboratories, Algorithm, Diagnosis, History, MPH, Harvard Medical School, Mass General Brigham, Genetic testing, Thermo Fisher Scientific, Vaccine

YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series. This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.

Key Points: 
  • Join Labroots on May 15, 2024, for the 12th Annual Precision Medicine Virtual Event Series, exploring the latest in genomics, genetics, and molecular diagnostics, with keynote speakers, dynamic sessions, and opportunities for continuing education.
  • YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series .
  • This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.
  • This year's event will dive deep into the cutting-edge areas of genomics, genetics, and molecular diagnostics, pivotal in the ongoing revolution of personalized healthcare.

Calico and Broad Institute Extend Collaboration Adding Focus on Age-Related Neurodegeneration

Retrieved on: 
Thursday, May 9, 2024
Brain, Harvard University, Genetics, Broad Institute, Disease, Biomedical Research, Partnership, Research, Patient, Biology, Notifiable disease, Calico (company), Ageing, Drug discovery, PTPN2, Organization, SAN, MIT, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico) and the Broad Institute of MIT and Harvard, announced today that the two organizations have further extended their partnership with an added focus on age-related neurodegeneration.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico) and the Broad Institute of MIT and Harvard, announced today that the two organizations have further extended their partnership with an added focus on age-related neurodegeneration.
  • "We are pleased to continue our collaboration with the Broad Institute.
  • "Renewing our commitment to this partnership with Calico reflects our shared goal of advancing transformative biomedical research and therapies for age-related diseases," said Todd Golub, M.D., Director and founding core member of the Broad Institute.
  • We look forward to working with the Calico team to further our insights into how aging impacts the brain and neurological function."

World's Most Influential People in Ophthalmology

Retrieved on: 
Thursday, May 9, 2024
Education, FDA, Bascom Palmer Eye Institute, Genetics, Teaching, Surgeon, Paratriathlon, Neuro-ophthalmology, Leach, Strabismus, Cataract, Knowledge, Bascom H. Palmer, Gedde, Eye, DRS, Retina, Vision science, Quality of life, Publication, Research, Bevacizumab, Artificial intelligence, Suture, Health, M.A, Choroideremia, Medeiros, Vance DeGeneres, University, Retinitis pigmentosa, Epidemiology, American Journal, Power, Patient, Physician, Uveitis, Glaucoma, Nursing

MIAMI, May 9, 2024 /PRNewswire/ -- Fifteen Bascom Palmer Eye Institute physicians were selected for the 2024 Power List, a prestigious selection of the world's 100 most influential people shaping the future of eye care, as published by The Ophthalmologist magazine. Drs. Eduardo C. Alfonso, Kendall Donaldson, Hilda Capó, Janet Davis, Harry Flynn, Anat Galor, Steven Gedde, Ranya Habash, Carol Karp, Jaclyn Kovach, Byron Lam, Felipe Medeiros, Richard Parrish, Philip Rosenfeld, and Sonia Yoo were named to the 2024 Power List. Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.

Key Points: 
  • Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.
  • From cutting-edge treatments to groundbreaking research, these doctors are pushing boundaries and setting new standards in ophthalmology."
  • Alfonso, the holder of the Kathleen and Stanley J. Glaser Chair in Ophthalmology, was also named to the Ophthalmologist Power Lists 2014, 2016, 2018, 2022, and 2023.
  • Holder of the John T. Flynn Chair in Ophthalmology, Hilda Capó, M.D., specializes in pediatric ophthalmology and adult strabismus.

EQS-News: Acquisition of WEECO Pharma: SYNBIOTIC significantly expands its position in the medical cannabis market

Retrieved on: 
Friday, May 10, 2024
Genetics, Flower, Acquisition, Dronabinol, GMP, Pharmacy, Drug

The German industrial hemp and cannabis group SYNBIOTIC SE acquires WEECO Pharma GmbH from Hildesheim/Germany.

Key Points: 
  • The German industrial hemp and cannabis group SYNBIOTIC SE acquires WEECO Pharma GmbH from Hildesheim/Germany.
  • The merger makes SYNBIOTIC one of the most important players on the German and European market for medicinal cannabis.
  • "This will significantly strengthen our market position in the medical cannabis market."
  • "The acquisition of WEECO Pharma is another key milestone in our successful buy and build strategy," says Daniel Kruse, CEO SYNBIOTIC.

23andMe to Report Q4 and Full Year FY2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024
Genome, Webcast, Genetics, SAN, Q&A

The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year’s financial results and report on business progress.

Key Points: 
  • The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year’s financial results and report on business progress.
  • The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations .
  • A webcast replay will be available at the same address following the event.
  • In addition, 23andMe will use the Say Technologies platform to allow retail and institutional shareholders to submit and upvote questions to management in advance of the earnings conference call.

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

Retrieved on: 
Thursday, May 9, 2024
Public, Genetics, RC, Malaria, Health, Cardiology, WGS, KFSH, ANFAL, Organ transplantation, Conditional sentence, Life expectancy, Harmony, TPV, Harvard University

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care.

Key Points: 
  • RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care.
  • These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom.
  • KFSH&RC’s digital health initiatives extend to addressing broader health threats through technologies such as Whole Genomic Sequencing (WGS) and Advanced Radiation Therapy.
  • Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country's top ten most valuable brands.

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2024
Genetics, Liver disease, Coronary artery disease, Research, N-Acetylgalactosamine, Weight loss, Doctor of Philosophy, Webcast, SVP, DSM-IV codes, CSO, Biomarker, Drug discovery, AATD, RNA editing, Activin and inhibin, Facial muscles, Pharmacokinetics, LNP, SAD, GSK, Serum, Duchenne muscular dystrophy, HTT, Cerebrospinal fluid, MASH, Weight, Safety, Health, RNA, Obesity, Human, Therapy, HD, Central nervous system, Clinical trial, ED50, Small RNA, Stanford University, Lof, Genomics, Exon, Science, Senior, Patient, Cardiovascular disease, MBA, PD, Lipolysis, Q&A, Pharmaceutical industry

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Revenue was $12.5 million for the first quarter of 2024, as compared to $12.9 million in the first quarter of 2023.
  • Net loss was $31.6 million for the first quarter of 2024, as compared to $27.4 million for the first quarter of 2023.
  • ET to review the first quarter 2024 financial results and pipeline updates.

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

Retrieved on: 
Thursday, May 9, 2024
Stanford University, Genetics, Genomics, RNA editing, University of Oxford, Molecular epidemiology, Health, Gene editing, RNA, Doctor of Philosophy, Computational biology, Research, Employment, Obesity, Therapy, Senior, SVP, GSK, Patient, DSM-IV codes, Faculty, Cardiovascular disease, Karolinska Institute, MBA, Biology, Framingham Heart Study, RSU, Drug discovery, MASH, Insulin resistance, Pharmaceutical industry

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer.

Key Points: 
  • CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer.
  • Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK.
  • Dr. Ingelsson brings to Wave deep expertise in genetics and drug discovery, as well as substantial experience in metabolic diseases.
  • He will leverage his experience to accelerate identification of new genetic insights and rapidly translate those insights into RNA medicines at Wave, including with our wholly owned INHBE program for obesity,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

Cronos Group Reports 2024 First Quarter Results

Retrieved on: 
Thursday, May 9, 2024
Cream, Mazor Robotics, Genetics, Certified Public Accountant, Wedding cake, Investment, Fully Charged, Average cost, Capital, EY, Pharma, Depreciation, Cannabinol, Flower, Robotics, Traction, GMO, Partnership, Research, Capital expenditure, Medtronic, Tax, Senior, Patient, Vii, Hamas, CBC, Motus, CBN, Lord, CBG, Growth, Drug

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results.

Key Points: 
  • Cronos Growing Company Inc. ("Cronos GrowCo") reported to the Company preliminary unaudited net revenue to licensed producers, excluding sales to the Company, of approximately $5.1 million in the first quarter of 2024.
  • Cronos previously provided Cronos GrowCo with a senior secured credit facility, which currently has approximately $67.1 million outstanding following a principal repayment of $1.2 million by Cronos GrowCo in Q1 2024.
  • In addition to principal repayment, Cronos also received $1.4 million in interest payments from Cronos GrowCo, totaling approximately $2.7 million in cash payments to Cronos in Q1 2024.
  • Before becoming Head of Cronos Israel, he was the Vice President of Finance at Cronos Israel managing the Cronos Israel finance department.

Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol

Retrieved on: 
Wednesday, May 8, 2024
UCLA, Stargardt disease, Stargardt, Research, Paratriathlon, Genetics, Retina, Patient, Human genetics, The central science, ABCA4, Clinical trial, Annual general meeting, ARVO, Vitamin A, Pharmaceutical industry

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced the presentation of positive interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic for the duration of therapy ranging between two and six years.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced the presentation of positive interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic for the duration of therapy ranging between two and six years.
  • Results were presented during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9 in Seattle.
  • “These exciting results demonstrate the potential of gildeuretinol acetate to prevent vision loss in early-stage Stargardt patients,” said Leonide Saad, Ph.D., President and CEO of Alkeus Pharmaceuticals.
  • All of us working in our growing Alkeus team are committed to advancing research and having an impact on patients living with vision loss.